Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the... 
Via Benzinga
News headline image
Earnings Scheduled For February 16, 2022 ↗
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
News headline image
EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder ↗
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has  
Via Benzinga
News headline image
Analyst Ratings For Blueprint Medicines ↗
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BP... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
News headline image
Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies ↗
Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies.... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
News headline image
Where Blueprint Medicines Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
Analyst Ratings for Blueprint Medicines ↗
Blueprint Medicines (NASDAQ:BPMC) has observed the followi... 
Via Benzinga
News headline image
Earnings Preview: Blueprint Medicines ↗
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Needham cut Medtronic plc (NYSE:MDT) price target f... 
Via Benzinga
News headline image
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... 
Via Benzinga
News headline image
34 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage... 
Via Benzinga
News headline image
Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition ↗
Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration... 
Via Benzinga
News headline image
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million ↗
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics. 
Via Talk Markets
News headline image
Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates ↗
Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in... 
Via Benzinga
News headline image
Blueprint Medicines Corp (BPMC) Q3 2021 Earnings Call Transcript ↗
BPMC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
News headline image
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar ↗
Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Blueprint Medicines: Q2 Earnings Insights ↗
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs ↗
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.